Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar;16(3):375-380.
doi: 10.1016/j.jtho.2020.12.008. Epub 2020 Dec 26.

Statistical Considerations for Subgroup Analyses

Xiaofei Wang  1 , Steven Piantadosi  2 , Jennifer Le-Rademacher  3 , Sumithra J Mandrekar  3
Affiliations

Statistical Considerations for Subgroup Analyses

Xiaofei Wang et al. J Thorac Oncol. 2021 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure

The authors declare no conflict of interest.

Figures

Figure 1.
Figure 1.
Types of treatment-by-subgroup interaction – no interaction (A), quantitative interaction (B) and qualitative interaction (C). The Y-axis denotes the treatment effect, e.g. the Hazard Ratio (HR) for Ctrl vs. Trt. A treatment effect 1 indicates the treatment is as effective as the control; a treatment effect greater than 1 indicates the treatment is better than the control; and a treatment effect less than 1 indicates the treatment is worse than the control.
Figure 2.
Figure 2.
Schematic plot of qualitative interaction between treatment and EGFR mutation observed in IPASS trial.
See this image and copyright information in PMC

References

    1. Lewis JA (1999). Statistical principles for clinical trials (ICH E9): an introductory note on an international guideline. Statistics in Medicine, 18(15), 1903–1942. - PubMed
    1. FDA Guidance for Industry (2012). Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products.
    1. European Medicines Agency. (2014). Guideline on the investigation of subgroups in confirmatory clinical trials. EMA/CHMP/539146.
    1. Dmitrienko A, Muysers C, Fritsch A, & Lipkovich I (2016). General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials. Journal of Biopharmaceutical statistics, 26(1), 71–98. - PubMed
    1. Alosh M, Huque MF, Bretz F, & D’Agostino RB Sr (2017). Tutorial on statistical considerations on subgroup analysis in confirmatory clinical trials. Statistics in Medicine, 36(8), 1334–1360. - PubMed

Publication types